Online inquiry

IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4295MR)

This product GTTS-WQ4295MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4295MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12764MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ14410MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ1951MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ8939MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ11761MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ10997MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ5710MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ12290MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW